-
1
-
-
77949875356
-
Nuclear receptors, inflammation, and liver disease: Insights for cholestatic and fatty liver diseases
-
Arrese M., Karpen S. J. Nuclear receptors, inflammation, and liver disease: Insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther: 2010; 87 4 473 478
-
(2010)
Clin Pharmacol Ther
, vol.87
, Issue.4
, pp. 473-478
-
-
Arrese, M.1
Karpen, S.J.2
-
2
-
-
0023857147
-
Identification of a new class of steroid hormone receptors
-
Giguère V., Yang N., Segui P., Evans R. M. Identification of a new class of steroid hormone receptors. Nature: 1988; 331 6151 91 94
-
(1988)
Nature
, vol.331
, Issue.6151
, pp. 91-94
-
-
Giguère, V.1
Yang, N.2
Segui, P.3
Evans, R.M.4
-
3
-
-
65549145901
-
Nuclear receptors as therapeutic targets in cholestatic liver diseases
-
Zollner G., Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol: 2009; 156 1 7 27
-
(2009)
Br J Pharmacol
, vol.156
, Issue.1
, pp. 7-27
-
-
Zollner, G.1
Trauner, M.2
-
4
-
-
84887599824
-
Bile acid-mediated control of liver triglycerides
-
Fuchs C., Claudel T., Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis: 2013; 33 4 330 342
-
(2013)
Semin Liver Dis
, vol.33
, Issue.4
, pp. 330-342
-
-
Fuchs, C.1
Claudel, T.2
Trauner, M.3
-
5
-
-
37349114118
-
Nuclear receptors: Decoding metabolic disease
-
Sonoda J., Pei L., Evans R. M. Nuclear receptors: Decoding metabolic disease. FEBS Lett: 2008; 582 1 2 9
-
(2008)
FEBS Lett
, vol.582
, Issue.1
, pp. 2-9
-
-
Sonoda, J.1
Pei, L.2
Evans, R.M.3
-
6
-
-
79952227694
-
Nuclear receptors in liver disease
-
Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology: 2011; 53 3 1023 1034
-
(2011)
Hepatology
, vol.53
, Issue.3
, pp. 1023-1034
-
-
Wagner, M.1
Zollner, G.2
Trauner, M.3
-
7
-
-
8844262660
-
Principles for modulation of the nuclear receptor superfamily
-
Gronemeyer H., Gustafsson J. A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov: 2004; 3 11 950 964
-
(2004)
Nat Rev Drug Discov
, vol.3
, Issue.11
, pp. 950-964
-
-
Gronemeyer, H.1
Gustafsson, J.A.2
Laudet, V.3
-
8
-
-
0032532721
-
Orphan nuclear receptors-new ligands and new possibilities
-
Blumberg B., Evans R. M. Orphan nuclear receptors -new ligands and new possibilities. Genes Dev: 1998; 12 20 3149 3155
-
(1998)
Genes Dev
, vol.12
, Issue.20
, pp. 3149-3155
-
-
Blumberg, B.1
Evans, R.M.2
-
9
-
-
36849084107
-
Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta
-
Raghuram S., Stayrook K. R., Huang P., et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol: 2007; 14 12 1207 1213
-
(2007)
Nat Struct Mol Biol
, vol.14
, Issue.12
, pp. 1207-1213
-
-
Raghuram, S.1
Stayrook, K.R.2
Huang, P.3
-
10
-
-
84922901154
-
Identification of natural RORγ ligands that regulate the development of lymphoid cells
-
Santori F. R., Huang P., van de Pavert S. A., et al. Identification of natural RORγ ligands that regulate the development of lymphoid cells. Cell Metab: 2015; 21 2 286 297
-
(2015)
Cell Metab
, vol.21
, Issue.2
, pp. 286-297
-
-
Santori, F.R.1
Huang, P.2
Van De Pavert, S.A.3
-
11
-
-
0037129380
-
Nonalcoholic fatty liver disease
-
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med: 2002; 346 16 1221 1231
-
(2002)
N Engl J Med
, vol.346
, Issue.16
, pp. 1221-1231
-
-
Angulo, P.1
-
12
-
-
0027447461
-
Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers
-
Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A: 1993; 90 6 2160 2164
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, Issue.6
, pp. 2160-2164
-
-
Keller, H.1
Dreyer, C.2
Medin, J.3
Mahfoudi, A.4
Ozato, K.5
Wahli, W.6
-
13
-
-
0033998334
-
The PPARs: From orphan receptors to drug discovery
-
Willson T. M., Brown P. J., Sternbach D. D., Henke B. R. The PPARs: From orphan receptors to drug discovery. J Med Chem: 2000; 43 4 527 550
-
(2000)
J Med Chem
, vol.43
, Issue.4
, pp. 527-550
-
-
Willson, T.M.1
Brown, P.J.2
Sternbach, D.D.3
Henke, B.R.4
-
14
-
-
0034669025
-
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta
-
Repa J. J., Liang G., Ou J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev: 2000; 14 22 2819 2830
-
(2000)
Genes Dev
, vol.14
, Issue.22
, pp. 2819-2830
-
-
Repa, J.J.1
Liang, G.2
Ou, J.3
-
15
-
-
0013199471
-
Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha
-
Peet D. J., Turley S. D., Ma W., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell: 1998; 93 5 693 704
-
(1998)
Cell
, vol.93
, Issue.5
, pp. 693-704
-
-
Peet, D.J.1
Turley, S.D.2
Ma, W.3
-
16
-
-
0033591297
-
Identification of a nuclear receptor for bile acids
-
Makishima M., Okamoto A. Y., Repa J. J., et al. Identification of a nuclear receptor for bile acids. Science: 1999; 284 5418 1362 1365
-
(1999)
Science
, vol.284
, Issue.5418
, pp. 1362-1365
-
-
Makishima, M.1
Okamoto, A.Y.2
Repa, J.J.3
-
17
-
-
0033591387
-
Bile acids: Natural ligands for an orphan nuclear receptor
-
Parks D. J., Blanchard S. G., Bledsoe R. K., et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science: 1999; 284 5418 1365 1368
-
(1999)
Science
, vol.284
, Issue.5418
, pp. 1365-1368
-
-
Parks, D.J.1
Blanchard, S.G.2
Bledsoe, R.K.3
-
18
-
-
0033026760
-
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR
-
Wang H., Chen J., Hollister K., Sowers L. C., Forman B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell: 1999; 3 5 543 553
-
(1999)
Mol Cell
, vol.3
, Issue.5
, pp. 543-553
-
-
Wang, H.1
Chen, J.2
Hollister, K.3
Sowers, L.C.4
Forman, B.M.5
-
19
-
-
84880664792
-
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
-
Mudaliar S., Henry R. R., Sanyal A. J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 3 574 82.e1
-
(2013)
Gastroenterology
, vol.145
, Issue.3
, pp. 574-82e1
-
-
Mudaliar, S.1
Henry, R.R.2
Sanyal, A.J.3
-
20
-
-
65749115425
-
Non alcoholic fatty liver disease and metabolic syndrome
-
Paschos P., Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia: 2009; 13 1 9 19
-
(2009)
Hippokratia
, vol.13
, Issue.1
, pp. 9-19
-
-
Paschos, P.1
Paletas, K.2
-
21
-
-
84859157277
-
Roles of PPARs in NAFLD: Potential therapeutic targets
-
Tailleux A., Wouters K., Staels B. Roles of PPARs in NAFLD: Potential therapeutic targets. Biochim Biophys Acta: 2012; 1821 5 809 818
-
(2012)
Biochim Biophys Acta
, vol.1821
, Issue.5
, pp. 809-818
-
-
Tailleux, A.1
Wouters, K.2
Staels, B.3
-
22
-
-
33644652183
-
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
-
Lefebvre P., Chinetti G., Fruchart J. C., Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest: 2006; 116 3 571 580
-
(2006)
J Clin Invest
, vol.116
, Issue.3
, pp. 571-580
-
-
Lefebvre, P.1
Chinetti, G.2
Fruchart, J.C.3
Staels, B.4
-
23
-
-
50649089597
-
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
-
Staels B., Maes M., Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med: 2008; 5 9 542 553
-
(2008)
Nat Clin Pract Cardiovasc Med
, vol.5
, Issue.9
, pp. 542-553
-
-
Staels, B.1
Maes, M.2
Zambon, A.3
-
24
-
-
0035024343
-
A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle
-
Minnich A., Tian N., Byan L., Bilder G. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab: 2001; 280 2 E270 E279
-
(2001)
Am J Physiol Endocrinol Metab
, vol.280
, Issue.2
, pp. E270-E279
-
-
Minnich, A.1
Tian, N.2
Byan, L.3
Bilder, G.4
-
25
-
-
0028817459
-
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
-
Staels B., Vu-Dac N., Kosykh V. A., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest: 1995; 95 2 705 712
-
(1995)
J Clin Invest
, vol.95
, Issue.2
, pp. 705-712
-
-
Staels, B.1
Vu-Dac, N.2
Kosykh, V.A.3
-
26
-
-
0037438377
-
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation
-
Kleemann R., Gervois P. P., Verschuren L., Staels B., Princen H. M., Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood: 2003; 101 2 545 551
-
(2003)
Blood
, vol.101
, Issue.2
, pp. 545-551
-
-
Kleemann, R.1
Gervois, P.P.2
Verschuren, L.3
Staels, B.4
Princen, H.M.5
Kooistra, T.6
-
27
-
-
0032565868
-
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
-
Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature: 1998; 393 6687 790 793
-
(1998)
Nature
, vol.393
, Issue.6687
, pp. 790-793
-
-
Staels, B.1
Koenig, W.2
Habib, A.3
-
28
-
-
70350133800
-
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease
-
Belvisi M. G., Mitchell J. A. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol: 2009; 158 4 994 1003
-
(2009)
Br J Pharmacol
, vol.158
, Issue.4
, pp. 994-1003
-
-
Belvisi, M.G.1
Mitchell, J.A.2
-
29
-
-
0034666132
-
Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting
-
Hashimoto T., Cook W. S., Qi C., Yeldandi A. V., Reddy J. K., Rao M. S. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem: 2000; 275 37 28918 28928
-
(2000)
J Biol Chem
, vol.275
, Issue.37
, pp. 28918-28928
-
-
Hashimoto, T.1
Cook, W.S.2
Qi, C.3
Yeldandi, A.V.4
Reddy, J.K.5
Rao, M.S.6
-
30
-
-
0033516569
-
Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype
-
Hashimoto T., Fujita T., Usuda N., et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem: 1999; 274 27 19228 19236
-
(1999)
J Biol Chem
, vol.274
, Issue.27
, pp. 19228-19236
-
-
Hashimoto, T.1
Fujita, T.2
Usuda, N.3
-
31
-
-
0141446024
-
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
-
Gavrilova O., Haluzik M., Matsusue K., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem: 2003; 278 36 34268 34276
-
(2003)
J Biol Chem
, vol.278
, Issue.36
, pp. 34268-34276
-
-
Gavrilova, O.1
Haluzik, M.2
Matsusue, K.3
-
32
-
-
0037373008
-
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
-
Matsusue K., Haluzik M., Lambert G., et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest: 2003; 111 5 737 747
-
(2003)
J Clin Invest
, vol.111
, Issue.5
, pp. 737-747
-
-
Matsusue, K.1
Haluzik, M.2
Lambert, G.3
-
33
-
-
77951457202
-
Fibrates, glitazones, and peroxisome proliferator-activated receptors
-
Lalloyer F., Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol: 2010; 30 5 894 899
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, Issue.5
, pp. 894-899
-
-
Lalloyer, F.1
Staels, B.2
-
34
-
-
67649090459
-
Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
-
Fiévet C., Staels B. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Curr Atheroscler Rep: 2009; 11 4 281 288
-
(2009)
Curr Atheroscler Rep
, vol.11
, Issue.4
, pp. 281-288
-
-
Fiévet, C.1
Staels, B.2
-
35
-
-
49649129066
-
Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice
-
Qin X., Xie X., Fan Y., et al. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology: 2008; 48 2 432 441
-
(2008)
Hepatology
, vol.48
, Issue.2
, pp. 432-441
-
-
Qin, X.1
Xie, X.2
Fan, Y.3
-
36
-
-
0038643427
-
Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice
-
Ip E., Farrell G. C., Robertson G., Hall P., Kirsch R., Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology: 2003; 38 1 123 132
-
(2003)
Hepatology
, vol.38
, Issue.1
, pp. 123-132
-
-
Ip, E.1
Farrell, G.C.2
Robertson, G.3
Hall, P.4
Kirsch, R.5
Leclercq, I.6
-
37
-
-
34250821923
-
Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation
-
Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., Müller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology: 2007; 148 6 2753 2763
-
(2007)
Endocrinology
, vol.148
, Issue.6
, pp. 2753-2763
-
-
Stienstra, R.1
Mandard, S.2
Patsouris, D.3
Maass, C.4
Kersten, S.5
Müller, M.6
-
38
-
-
79959696573
-
Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice
-
Lalloyer F., Wouters K., Baron M., et al. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol: 2011; 31 7 1573 1579
-
(2011)
Arterioscler Thromb Vasc Biol
, vol.31
, Issue.7
, pp. 1573-1579
-
-
Lalloyer, F.1
Wouters, K.2
Baron, M.3
-
39
-
-
33644919989
-
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates
-
Shiri-Sverdlov R., Wouters K., van Gorp P. J., et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol: 2006; 44 4 732 741
-
(2006)
J Hepatol
, vol.44
, Issue.4
, pp. 732-741
-
-
Shiri-Sverdlov, R.1
Wouters, K.2
Van Gorp, P.J.3
-
40
-
-
2342644813
-
Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice
-
Ip E., Farrell G., Hall P., Robertson G., Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology: 2004; 39 5 1286 1296
-
(2004)
Hepatology
, vol.39
, Issue.5
, pp. 1286-1296
-
-
Ip, E.1
Farrell, G.2
Hall, P.3
Robertson, G.4
Leclercq, I.5
-
41
-
-
2542465868
-
Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro
-
Kleemann R., Verschuren L., de Rooij B. J., et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood: 2004; 103 11 4188 4194
-
(2004)
Blood
, vol.103
, Issue.11
, pp. 4188-4194
-
-
Kleemann, R.1
Verschuren, L.2
De Rooij, B.J.3
-
42
-
-
47949094965
-
Integration of metabolism and inflammation by lipid-activated nuclear receptors
-
Bensinger S. J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature: 2008; 454 7203 470 477
-
(2008)
Nature
, vol.454
, Issue.7203
, pp. 470-477
-
-
Bensinger, S.J.1
Tontonoz, P.2
-
43
-
-
84931577111
-
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
-
Francque S., Verrijken A., Caron S., et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol: 2015; 63 1 164 173
-
(2015)
J Hepatol
, vol.63
, Issue.1
, pp. 164-173
-
-
Francque, S.1
Verrijken, A.2
Caron, S.3
-
44
-
-
84929728792
-
Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
-
Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol: 2015; 7 8 1012 1019
-
(2015)
World J Hepatol
, vol.7
, Issue.8
, pp. 1012-1019
-
-
Souza-Mello, V.1
-
45
-
-
0344874601
-
Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives
-
Chapman M. J. Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis: 2003; 171 1 1 13
-
(2003)
Atherosclerosis
, vol.171
, Issue.1
, pp. 1-13
-
-
Chapman, M.J.1
-
46
-
-
84866146620
-
Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline
-
Endocrine society
-
Berglund L., Brunzell J. D., Goldberg A. C., et al. Endocrine society. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab: 2012; 97 9 2969 2989
-
(2012)
J Clin Endocrinol Metab
, vol.97
, Issue.9
, pp. 2969-2989
-
-
Berglund, L.1
Brunzell, J.D.2
Goldberg, A.C.3
-
47
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
FIELD study investigators.
-
Keech A., Simes R. J., Barter P., et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet: 2005; 366 9500 1849 1861
-
(2005)
Lancet
, vol.366
, Issue.9500
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
-
48
-
-
50549084740
-
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
-
Ong J. P., Pitts A., Younossi Z. M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol: 2008; 49 4 608 612
-
(2008)
J Hepatol
, vol.49
, Issue.4
, pp. 608-612
-
-
Ong, J.P.1
Pitts, A.2
Younossi, Z.M.3
-
49
-
-
84928209634
-
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
-
Ekstedt M., Hagström H., Nasr P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology: 2015; 61 5 1547 1554
-
(2015)
Hepatology
, vol.61
, Issue.5
, pp. 1547-1554
-
-
Ekstedt, M.1
Hagström, H.2
Nasr, P.3
-
50
-
-
84885769159
-
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
-
Kostapanos M. S., Kei A., Elisaf M. S. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol: 2013; 5 9 470 478
-
(2013)
World J Hepatol
, vol.5
, Issue.9
, pp. 470-478
-
-
Kostapanos, M.S.1
Kei, A.2
Elisaf, M.S.3
-
51
-
-
33745046866
-
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study
-
Athyros V. G., Mikhailidis D. P., Didangelos T. P., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr Med Res Opin: 2006; 22 5 873 883
-
(2006)
Curr Med Res Opin
, vol.22
, Issue.5
, pp. 873-883
-
-
Athyros, V.G.1
Mikhailidis, D.P.2
Didangelos, T.P.3
-
52
-
-
34447114640
-
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
-
Bajaj M., Suraamornkul S., Hardies L. J., Glass L., Musi N., DeFronzo R. A. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia: 2007; 50 8 1723 1731
-
(2007)
Diabetologia
, vol.50
, Issue.8
, pp. 1723-1731
-
-
Bajaj, M.1
Suraamornkul, S.2
Hardies, L.J.3
Glass, L.4
Musi, N.5
DeFronzo, R.A.6
-
53
-
-
38749085998
-
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
-
Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J. A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis: 2008; 40 3 200 205
-
(2008)
Dig Liver Dis
, vol.40
, Issue.3
, pp. 200-205
-
-
Fernández-Miranda, C.1
Pérez-Carreras, M.2
Colina, F.3
López-Alonso, G.4
Vargas, C.5
Solís-Herruzo, J.A.6
-
54
-
-
84933047295
-
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
-
Laurin J., Lindor K. D., Crippin J. S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology: 1996; 23 6 1464 1467
-
(1996)
Hepatology
, vol.23
, Issue.6
, pp. 1464-1467
-
-
Laurin, J.1
Lindor, K.D.2
Crippin, J.S.3
-
55
-
-
84858703583
-
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
-
Parker H. M., Johnson N. A., Burdon C. A., Cohn J. S., O'Connor H. T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol: 2012; 56 4 944 951
-
(2012)
J Hepatol
, vol.56
, Issue.4
, pp. 944-951
-
-
Parker, H.M.1
Johnson, N.A.2
Burdon, C.A.3
Cohn, J.S.4
O'Connor, H.T.5
George, J.6
-
56
-
-
79451476075
-
The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease
-
Shapiro H., Tehilla M., Attal-Singer J., Bruck R., Luzzatti R., Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr: 2011; 30 1 6 19
-
(2011)
Clin Nutr
, vol.30
, Issue.1
, pp. 6-19
-
-
Shapiro, H.1
Tehilla, M.2
Attal-Singer, J.3
Bruck, R.4
Luzzatti, R.5
Singer, P.6
-
57
-
-
84930268665
-
Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
-
Nogueira M. A., Oliveira C. P., Ferreira Alves V. A., et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clin Nutr: 2015
-
(2015)
Clin Nutr
-
-
Nogueira, M.A.1
Oliveira, C.P.2
Ferreira Alves, V.A.3
-
58
-
-
84878349086
-
Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
-
Fruchart J. C. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol: 2013; 12 82
-
(2013)
Cardiovasc Diabetol
, vol.12
, pp. 82
-
-
Fruchart, J.C.1
-
59
-
-
84885405205
-
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects
-
Cariou B., Hanf R., Lambert-Porcheron S., et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care: 2013; 36 10 2923 2930
-
(2013)
Diabetes Care
, vol.36
, Issue.10
, pp. 2923-2930
-
-
Cariou, B.1
Hanf, R.2
Lambert-Porcheron, S.3
-
60
-
-
84888285959
-
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
-
Staels B., Rubenstrunk A., Noel B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology: 2013; 58 6 1941 1952
-
(2013)
Hepatology
, vol.58
, Issue.6
, pp. 1941-1952
-
-
Staels, B.1
Rubenstrunk, A.2
Noel, B.3
-
61
-
-
84968850631
-
An international, phase 2 randomized controlled trial of the dual PPAR α-δ agonist GFT505 in adult patients with NASH
-
Ratziu V., Bedossa P., et al. An international, phase 2 randomized controlled trial of the dual PPAR α-δ agonist GFT505 in adult patients with NASH. Hepatology: 2015; 62 (S1): 262A
-
(2015)
Hepatology
, vol.62
, pp. 262A
-
-
Ratziu, V.1
Bedossa, P.2
-
62
-
-
79751491258
-
Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice
-
Nan Y. M., Han F., Kong L. B., et al. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol: 2011; 46 3 358 369
-
(2011)
Scand J Gastroenterol
, vol.46
, Issue.3
, pp. 358-369
-
-
Nan, Y.M.1
Han, F.2
Kong, L.B.3
-
63
-
-
0036381998
-
Adipose tissue as a buffer for daily lipid flux
-
Frayn K. N. Adipose tissue as a buffer for daily lipid flux. Diabetologia: 2002; 45 9 1201 1210
-
(2002)
Diabetologia
, vol.45
, Issue.9
, pp. 1201-1210
-
-
Frayn, K.N.1
-
64
-
-
0035462629
-
PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
-
Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes: 2001; 50 9 2094 2099
-
(2001)
Diabetes
, vol.50
, Issue.9
, pp. 2094-2099
-
-
Maeda, N.1
Takahashi, M.2
Funahashi, T.3
-
65
-
-
17944365228
-
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
-
Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med: 2001; 7 8 941 946
-
(2001)
Nat Med
, vol.7
, Issue.8
, pp. 941-946
-
-
Yamauchi, T.1
Kamon, J.2
Waki, H.3
-
66
-
-
0037494960
-
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
-
Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature: 2003; 423 6941 762 769
-
(2003)
Nature
, vol.423
, Issue.6941
, pp. 762-769
-
-
Yamauchi, T.1
Kamon, J.2
Ito, Y.3
-
67
-
-
0033962940
-
Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells
-
Galli A., Crabb D., Price D., et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology: 2000; 31 1 101 108
-
(2000)
Hepatology
, vol.31
, Issue.1
, pp. 101-108
-
-
Galli, A.1
Crabb, D.2
Price, D.3
-
68
-
-
0034680787
-
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
-
Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem: 2000; 275 46 35715 35722
-
(2000)
J Biol Chem
, vol.275
, Issue.46
, pp. 35715-35722
-
-
Miyahara, T.1
Schrum, L.2
Rippe, R.3
-
69
-
-
0033855572
-
Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells
-
Marra F., Efsen E., Romanelli R. G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology: 2000; 119 2 466 478
-
(2000)
Gastroenterology
, vol.119
, Issue.2
, pp. 466-478
-
-
Marra, F.1
Efsen, E.2
Romanelli, R.G.3
-
70
-
-
33749341729
-
PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells
-
Zhao C., Chen W., Yang L., Chen L., Stimpson S. A., Diehl A. M. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun: 2006; 350 2 385 391
-
(2006)
Biochem Biophys Res Commun
, vol.350
, Issue.2
, pp. 385-391
-
-
Zhao, C.1
Chen, W.2
Yang, L.3
Chen, L.4
Stimpson, S.A.5
Diehl, A.M.6
-
71
-
-
14244257340
-
Adipogenic transcriptional regulation of hepatic stellate cells
-
She H., Xiong S., Hazra S., Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem: 2005; 280 6 4959 4967
-
(2005)
J Biol Chem
, vol.280
, Issue.6
, pp. 4959-4967
-
-
She, H.1
Xiong, S.2
Hazra, S.3
Tsukamoto, H.4
-
72
-
-
60349100000
-
Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma
-
Wang X., Huang G., Mei S., Qian J., Ji J., Zhang J. Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma. Biochem Biophys Res Commun: 2009; 380 2 286 291
-
(2009)
Biochem Biophys Res Commun
, vol.380
, Issue.2
, pp. 286-291
-
-
Wang, X.1
Huang, G.2
Mei, S.3
Qian, J.4
Ji, J.5
Zhang, J.6
-
73
-
-
0142093152
-
Peroxisome proliferator-activated receptors: New targets for the pharmacological modulation of macrophage gene expression and function
-
Chinetti G., Fruchart J. C., Staels B. Peroxisome proliferator-activated receptors: New targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol: 2003; 14 5 459 468
-
(2003)
Curr Opin Lipidol
, vol.14
, Issue.5
, pp. 459-468
-
-
Chinetti, G.1
Fruchart, J.C.2
Staels, B.3
-
74
-
-
34547492488
-
PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
-
Bouhlel M. A., Derudas B., Rigamonti E., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab: 2007; 6 2 137 143
-
(2007)
Cell Metab
, vol.6
, Issue.2
, pp. 137-143
-
-
Bouhlel, M.A.1
Derudas, B.2
Rigamonti, E.3
-
75
-
-
77957919796
-
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice
-
Foryst-Ludwig A., Hartge M., Clemenz M., et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol: 2010; 9 64
-
(2010)
Cardiovasc Diabetol
, vol.9
, pp. 64
-
-
Foryst-Ludwig, A.1
Hartge, M.2
Clemenz, M.3
-
76
-
-
84939938313
-
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
-
Watanabe S., Hashimoto E., Ikejima K., et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol: 2015; 50 4 364 377
-
(2015)
J Gastroenterol
, vol.50
, Issue.4
, pp. 364-377
-
-
Watanabe, S.1
Hashimoto, E.2
Ikejima, K.3
-
77
-
-
84861543083
-
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
-
Chalasani N., Younossi Z., Lavine J. E., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology: 2012; 55 6 2005 2023
-
(2012)
Hepatology
, vol.55
, Issue.6
, pp. 2005-2023
-
-
Chalasani, N.1
Younossi, Z.2
Lavine, J.E.3
-
78
-
-
33751545838
-
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
-
Belfort R., Harrison S. A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med: 2006; 355 22 2297 2307
-
(2006)
N Engl J Med
, vol.355
, Issue.22
, pp. 2297-2307
-
-
Belfort, R.1
Harrison, S.A.2
Brown, K.3
-
79
-
-
46349088361
-
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
-
LIDO Study Group
-
Ratziu V., Giral P., Jacqueminet S., et al. LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology: 2008; 135 1 100 110
-
(2008)
Gastroenterology
, vol.135
, Issue.1
, pp. 100-110
-
-
Ratziu, V.1
Giral, P.2
Jacqueminet, S.3
-
80
-
-
9644266912
-
Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial
-
Smith S. R., De Jonge L., Volaufova J., Li Y., Xie H., Bray G. A. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism: 2005; 54 1 24 32
-
(2005)
Metabolism
, vol.54
, Issue.1
, pp. 24-32
-
-
Smith, S.R.1
De Jonge, L.2
Volaufova, J.3
Li, Y.4
Xie, H.5
Bray, G.A.6
-
81
-
-
75449116707
-
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
-
LIDO Study Group
-
Ratziu V., Charlotte F., Bernhardt C., et al. LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology: 2010; 51 2 445 453
-
(2010)
Hepatology
, vol.51
, Issue.2
, pp. 445-453
-
-
Ratziu, V.1
Charlotte, F.2
Bernhardt, C.3
-
82
-
-
77951874018
-
Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis
-
NASH CRN
-
Sanyal A. J., Chalasani N., Kowdley K. V., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
-
(2010)
N Engl J Med
, vol.362
, Issue.18
, pp. 1675-1685
-
-
Sanyal, A.J.1
Chalasani, N.2
Kowdley, K.V.3
-
83
-
-
14944359845
-
A pilot study of Vitamin E versus Vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
-
Sanyal A. J., Mofrad P. S., Contos M. J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol: 2004; 2 12 1107 1115
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, Issue.12
, pp. 1107-1115
-
-
Sanyal, A.J.1
Mofrad, P.S.2
Contos, M.J.3
-
84
-
-
0141532275
-
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone
-
Neuschwander-Tetri B. A., Brunt E. M., Wehmeier K. R., Oliver D., Bacon B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology: 2003; 38 4 1008 1017
-
(2003)
Hepatology
, vol.38
, Issue.4
, pp. 1008-1017
-
-
Neuschwander-Tetri, B.A.1
Brunt, E.M.2
Wehmeier, K.R.3
Oliver, D.4
Bacon, B.R.5
-
85
-
-
0035120396
-
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
-
Caldwell S. H., Hespenheide E. E., Redick J. A., Iezzoni J. C., Battle E. H., Sheppard B. L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol: 2001; 96 2 519 525
-
(2001)
Am J Gastroenterol
, vol.96
, Issue.2
, pp. 519-525
-
-
Caldwell, S.H.1
Hespenheide, E.E.2
Redick, J.A.3
Iezzoni, J.C.4
Battle, E.H.5
Sheppard, B.L.6
-
86
-
-
78649596998
-
Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues
-
Ratziu V., Caldwell S., Neuschwander-Tetri B. A. Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology: 2010; 52 6 2206 2215
-
(2010)
Hepatology
, vol.52
, Issue.6
, pp. 2206-2215
-
-
Ratziu, V.1
Caldwell, S.2
Neuschwander-Tetri, B.A.3
-
87
-
-
84900822867
-
Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH
-
Cusi K., Orsak B., Lomonaco R., et al. Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH. Hepatology: 2013; 58 (S1): 248A
-
(2013)
Hepatology
, vol.58
, pp. 248A
-
-
Cusi, K.1
Orsak, B.2
Lomonaco, R.3
-
88
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen S. E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med: 2007; 356 24 2457 2471
-
(2007)
N Engl J Med
, vol.356
, Issue.24
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
89
-
-
84880919064
-
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
-
Mahaffey K. W., Hafley G., Dickerson S., et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J: 2013; 166 2 240 249.e1
-
(2013)
Am Heart J
, vol.166
, Issue.2
, pp. 240-249e1
-
-
Mahaffey, K.W.1
Hafley, G.2
Dickerson, S.3
-
90
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial
-
PROactive investigators
-
Dormandy J. A., Charbonnel B., Eckland D. J., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet: 2005; 366 9493 1279 1289
-
(2005)
Lancet
, vol.366
, Issue.9493
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
-
91
-
-
84890561445
-
Observational follow-up of the PROactive study: A 6-year update
-
Erdmann E., Song E., Spanheimer R., van Troostenburg de Bruyn A. R., Perez A. Observational follow-up of the PROactive study: A 6-year update. Diabetes Obes Metab: 2014; 16 1 63 74
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.1
, pp. 63-74
-
-
Erdmann, E.1
Song, E.2
Spanheimer, R.3
Van Troostenburg De Bruyn, A.R.4
Perez, A.5
-
92
-
-
84902603532
-
Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis
-
Turner R. M., Kwok C. S., Chen-Turner C., Maduakor C. A., Singh S., Loke Y. K. Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis. Br J Clin Pharmacol: 2014; 78 2 258 273
-
(2014)
Br J Clin Pharmacol
, vol.78
, Issue.2
, pp. 258-273
-
-
Turner, R.M.1
Kwok, C.S.2
Chen-Turner, C.3
Maduakor, C.A.4
Singh, S.5
Loke, Y.K.6
-
93
-
-
84924662049
-
Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis
-
Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium.
-
Levin D., Bell S., Sund R., et al. Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis. Diabetologia: 2015; 58 3 493 504
-
(2015)
Diabetologia
, vol.58
, Issue.3
, pp. 493-504
-
-
Levin, D.1
Bell, S.2
Sund, R.3
-
94
-
-
84908381489
-
L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation
-
Xie X., Zhou X., Chen W., et al. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation. Biochim Biophys Acta: 2015; 1850 1 62 72
-
(2015)
Biochim Biophys Acta
, vol.1850
, Issue.1
, pp. 62-72
-
-
Xie, X.1
Zhou, X.2
Chen, W.3
-
95
-
-
84903550477
-
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
-
INT131-007 Study Group
-
DePaoli A. M., Higgins L. S., Henry R. R., Mantzoros C., Dunn F. L.; INT131-007 Study Group. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care: 2014; 37 7 1918 1923
-
(2014)
Diabetes Care
, vol.37
, Issue.7
, pp. 1918-1923
-
-
DePaoli, A.M.1
Higgins, L.S.2
Henry, R.R.3
Mantzoros, C.4
Dunn, F.L.5
-
96
-
-
84878911175
-
Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis
-
quiz 892
-
Singh S., Singh P. P., Singh A. G., Murad M. H., Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol: 2013; 108 6 881 891, quiz 892
-
(2013)
Am J Gastroenterol
, vol.108
, Issue.6
, pp. 881-891
-
-
Singh, S.1
Singh, P.P.2
Singh, A.G.3
Murad, M.H.4
Sanchez, W.5
-
97
-
-
84874660234
-
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: Population-based and in vitro studies
-
Chen H-P, Shieh J. J., Chang C. C., et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: Population-based and in vitro studies. Gut: 2013; 62 4 606 615
-
(2013)
Gut
, vol.62
, Issue.4
, pp. 606-615
-
-
Chen, H.-P.1
Shieh, J.J.2
Chang, C.C.3
-
98
-
-
33645891166
-
Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- And choline-deficient diet
-
Nagasawa T., Inada Y., Nakano S., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- And choline-deficient diet. Eur J Pharmacol: 2006; 536 1-2 182 191
-
(2006)
Eur J Pharmacol
, vol.536
, Issue.1-2
, pp. 182-191
-
-
Nagasawa, T.1
Inada, Y.2
Nakano, S.3
-
99
-
-
0038153044
-
Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells
-
Hoekstra M., Kruijt J. K., Van Eck M., Van Berkel T. J. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem: 2003; 278 28 25448 25453
-
(2003)
J Biol Chem
, vol.278
, Issue.28
, pp. 25448-25453
-
-
Hoekstra, M.1
Kruijt, J.K.2
Van Eck, M.3
Van Berkel, T.J.4
-
100
-
-
44349112305
-
Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity
-
Kang K., Reilly S. M., Karabacak V., et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab: 2008; 7 6 485 495
-
(2008)
Cell Metab
, vol.7
, Issue.6
, pp. 485-495
-
-
Kang, K.1
Reilly, S.M.2
Karabacak, V.3
-
101
-
-
44349161098
-
Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance
-
Odegaard J. I., Ricardo-Gonzalez R. R., Red Eagle A., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab: 2008; 7 6 496 507
-
(2008)
Cell Metab
, vol.7
, Issue.6
, pp. 496-507
-
-
Odegaard, J.I.1
Ricardo-Gonzalez, R.R.2
Red Eagle, A.3
-
102
-
-
33846443997
-
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist
-
Sprecher D. L., Massien C., Pearce G., et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol: 2007; 27 2 359 365
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, Issue.2
, pp. 359-365
-
-
Sprecher, D.L.1
Massien, C.2
Pearce, G.3
-
103
-
-
39649101196
-
Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men
-
Risérus U., Sprecher D., Johnson T., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes: 2008; 57 2 332 339
-
(2008)
Diabetes
, vol.57
, Issue.2
, pp. 332-339
-
-
Risérus, U.1
Sprecher, D.2
Johnson, T.3
-
104
-
-
84865507796
-
Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: Characteristics of metabolic syndrome
-
Olson E. J., Pearce G. L., Jones N. P., Sprecher D. L. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol: 2012; 32 9 2289 2294
-
(2012)
Arterioscler Thromb Vasc Biol
, vol.32
, Issue.9
, pp. 2289-2294
-
-
Olson, E.J.1
Pearce, G.L.2
Jones, N.P.3
Sprecher, D.L.4
-
105
-
-
80052539818
-
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin
-
Bays H. E., Schwartz S., Littlejohn T. III., et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab: 2011; 96 9 2889 2897
-
(2011)
J Clin Endocrinol Metab
, vol.96
, Issue.9
, pp. 2889-2897
-
-
Bays, H.E.1
Schwartz, S.2
Littlejohn, T.3
-
106
-
-
84885400267
-
Peroxisome proliferator-activated receptor delta and cardiovascular disease
-
Ehrenborg E., Skogsberg J. Peroxisome proliferator-activated receptor delta and cardiovascular disease. Atherosclerosis: 2013; 231 1 95 106
-
(2013)
Atherosclerosis
, vol.231
, Issue.1
, pp. 95-106
-
-
Ehrenborg, E.1
Skogsberg, J.2
-
107
-
-
84893649359
-
New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
-
Sahebkar A., Chew G. T., Watts G. F. New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother: 2014; 15 4 493 503
-
(2014)
Expert Opin Pharmacother
, vol.15
, Issue.4
, pp. 493-503
-
-
Sahebkar, A.1
Chew, G.T.2
Watts, G.F.3
-
108
-
-
84861437351
-
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
-
Iwaisako K., Haimerl M., Paik Y. H., et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A: 2012; 109 21 E1369 E1376
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, Issue.21
, pp. E1369-E1376
-
-
Iwaisako, K.1
Haimerl, M.2
Paik, Y.H.3
-
109
-
-
58249110568
-
Role of bile acids and bile acid receptors in metabolic regulation
-
Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev: 2009; 89 1 147 191
-
(2009)
Physiol Rev
, vol.89
, Issue.1
, pp. 147-191
-
-
Lefebvre, P.1
Cariou, B.2
Lien, F.3
Kuipers, F.4
Staels, B.5
-
110
-
-
84865499656
-
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
-
Adorini L., Pruzanski M., Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today: 2012; 17 17-18 988 997
-
(2012)
Drug Discov Today
, vol.17
, Issue.17-18
, pp. 988-997
-
-
Adorini, L.1
Pruzanski, M.2
Shapiro, D.3
-
111
-
-
48749113401
-
Targeting bile-acid signalling for metabolic diseases
-
Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov: 2008; 7 8 678 693
-
(2008)
Nat Rev Drug Discov
, vol.7
, Issue.8
, pp. 678-693
-
-
Thomas, C.1
Pellicciari, R.2
Pruzanski, M.3
Auwerx, J.4
Schoonjans, K.5
-
112
-
-
84910031461
-
Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer
-
Tsuei J., Chau T., Mills D., Wan Y. J. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood): 2014; 239 11 1489 1504
-
(2014)
Exp Biol Med (Maywood)
, vol.239
, Issue.11
, pp. 1489-1504
-
-
Tsuei, J.1
Chau, T.2
Mills, D.3
Wan, Y.J.4
-
114
-
-
37349010675
-
FXR signaling in metabolic disease
-
Zhang Y., Edwards P. A. FXR signaling in metabolic disease. FEBS Lett: 2008; 582 1 10 18
-
(2008)
FEBS Lett
, vol.582
, Issue.1
, pp. 10-18
-
-
Zhang, Y.1
Edwards, P.A.2
-
115
-
-
77249108800
-
Bile acid sequestrants for lipid and glucose control
-
Staels B., Handelsman Y., Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep: 2010; 10 1 70 77
-
(2010)
Curr Diab Rep
, vol.10
, Issue.1
, pp. 70-77
-
-
Staels, B.1
Handelsman, Y.2
Fonseca, V.3
-
116
-
-
33645509321
-
Farnesoid X receptor is essential for normal glucose homeostasis
-
Ma K., Saha P. K., Chan L., Moore D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest: 2006; 116 4 1102 1109
-
(2006)
J Clin Invest
, vol.116
, Issue.4
, pp. 1102-1109
-
-
Ma, K.1
Saha, P.K.2
Chan, L.3
Moore, D.D.4
-
117
-
-
70349430938
-
Bile acids: Regulation of synthesis
-
Chiang J. Y. Bile acids: Regulation of synthesis. J Lipid Res: 2009; 50 10 1955 1966
-
(2009)
J Lipid Res
, vol.50
, Issue.10
, pp. 1955-1966
-
-
Chiang, J.Y.1
-
118
-
-
84870334072
-
Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo
-
Kir S., Zhang Y., Gerard R. D., Kliewer S. A., Mangelsdorf D. J. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem: 2012; 287 49 41334 41341
-
(2012)
J Biol Chem
, vol.287
, Issue.49
, pp. 41334-41341
-
-
Kir, S.1
Zhang, Y.2
Gerard, R.D.3
Kliewer, S.A.4
Mangelsdorf, D.J.5
-
119
-
-
84870556105
-
Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver
-
Cicione C., Degirolamo C., Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology: 2012; 56 6 2404 2411
-
(2012)
Hepatology
, vol.56
, Issue.6
, pp. 2404-2411
-
-
Cicione, C.1
Degirolamo, C.2
Moschetta, A.3
-
120
-
-
84946088116
-
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
-
Trabelsi M. S., Daoudi M., Prawitt J., et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun: 2015; 6 7629
-
(2015)
Nat Commun
, vol.6
, pp. 7629
-
-
Trabelsi, M.S.1
Daoudi, M.2
Prawitt, J.3
-
121
-
-
84895520482
-
The bile acid TGR5 membrane receptor: From basic research to clinical application
-
Duboc H., Taché Y., Hofmann A. F. The bile acid TGR5 membrane receptor: From basic research to clinical application. Dig Liver Dis: 2014; 46 4 302 312
-
(2014)
Dig Liver Dis
, vol.46
, Issue.4
, pp. 302-312
-
-
Duboc, H.1
Taché, Y.2
Hofmann, A.F.3
-
122
-
-
31444454037
-
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
-
Watanabe M., Houten S. M., Mataki C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature: 2006; 439 7075 484 489
-
(2006)
Nature
, vol.439
, Issue.7075
, pp. 484-489
-
-
Watanabe, M.1
Houten, S.M.2
Mataki, C.3
-
123
-
-
79955890870
-
Bile acid metabolism and the pathogenesis of type 2 diabetes
-
Prawitt J., Caron S., Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep: 2011; 11 3 160 166
-
(2011)
Curr Diab Rep
, vol.11
, Issue.3
, pp. 160-166
-
-
Prawitt, J.1
Caron, S.2
Staels, B.3
-
124
-
-
0034664729
-
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
-
Sinal C. J., Tohkin M., Miyata M., Ward J. M., Lambert G., Gonzalez F. J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell: 2000; 102 6 731 744
-
(2000)
Cell
, vol.102
, Issue.6
, pp. 731-744
-
-
Sinal, C.J.1
Tohkin, M.2
Miyata, M.3
Ward, J.M.4
Lambert, G.5
Gonzalez, F.J.6
-
125
-
-
33847044019
-
Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor
-
Yang F., Huang X., Yi T., Yen Y., Moore D. D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res: 2007; 67 3 863 867
-
(2007)
Cancer Res
, vol.67
, Issue.3
, pp. 863-867
-
-
Yang, F.1
Huang, X.2
Yi, T.3
Yen, Y.4
Moore, D.D.5
Huang, W.6
-
126
-
-
84946605496
-
FXR induces SOCS3 and suppresses hepatocellular carcinoma
-
Guo F., Xu Z., Zhang Y., et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget: 2015; 6 33 34606 34616
-
(2015)
Oncotarget
, vol.6
, Issue.33
, pp. 34606-34616
-
-
Guo, F.1
Xu, Z.2
Zhang, Y.3
-
127
-
-
84924231007
-
Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
-
Liu X., Zhang X., Ji L., Gu J., Zhou M., Chen S. Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget: 2015; 6 6 4226 4238
-
(2015)
Oncotarget
, vol.6
, Issue.6
, pp. 4226-4238
-
-
Liu, X.1
Zhang, X.2
Ji, L.3
Gu, J.4
Zhou, M.5
Chen, S.6
-
128
-
-
84920964414
-
Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation
-
Degirolamo C., Modica S., Vacca M., et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology: 2015; 61 1 161 170
-
(2015)
Hepatology
, vol.61
, Issue.1
, pp. 161-170
-
-
Degirolamo, C.1
Modica, S.2
Vacca, M.3
-
129
-
-
84924301185
-
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development
-
Uriarte I., Latasa M. U., Carotti S., et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer: 2015; 136 10 2469 2475
-
(2015)
Int J Cancer
, vol.136
, Issue.10
, pp. 2469-2475
-
-
Uriarte, I.1
Latasa, M.U.2
Carotti, S.3
-
130
-
-
84920971419
-
Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma
-
Gauglhofer C., Paur J., Schrottmaier W. C., et al. Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma. Carcinogenesis: 2014; 35 10 2331 2338
-
(2014)
Carcinogenesis
, vol.35
, Issue.10
, pp. 2331-2338
-
-
Gauglhofer, C.1
Paur, J.2
Schrottmaier, W.C.3
-
131
-
-
84887686733
-
FGFR4 and TGF-β1 expression in hepatocellular carcinoma: Correlation with clinicopathological features and prognosis
-
Chen Z., Xie B., Zhu Q., et al. FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis. Int J Med Sci: 2013; 10 13 1868 1875
-
(2013)
Int J Med Sci
, vol.10
, Issue.13
, pp. 1868-1875
-
-
Chen, Z.1
Xie, B.2
Zhu, Q.3
-
132
-
-
85047694456
-
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
-
Watanabe M., Houten S. M., Wang L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest: 2004; 113 10 1408 1418
-
(2004)
J Clin Invest
, vol.113
, Issue.10
, pp. 1408-1418
-
-
Watanabe, M.1
Houten, S.M.2
Wang, L.3
-
133
-
-
13844280404
-
Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor
-
Savkur R. S., Bramlett K. S., Michael L. F., Burris T. P. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem Biophys Res Commun: 2005; 329 1 391 396
-
(2005)
Biochem Biophys Res Commun
, vol.329
, Issue.1
, pp. 391-396
-
-
Savkur, R.S.1
Bramlett, K.S.2
Michael, L.F.3
Burris, T.P.4
-
134
-
-
67649210759
-
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
-
Zhang S., Wang J., Liu Q., Harnish D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol: 2009; 51 2 380 388
-
(2009)
J Hepatol
, vol.51
, Issue.2
, pp. 380-388
-
-
Zhang, S.1
Wang, J.2
Liu, Q.3
Harnish, D.C.4
-
135
-
-
0037101810
-
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
-
Pellicciari R., Fiorucci S., Camaioni E., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem: 2002; 45 17 3569 3572
-
(2002)
J Med Chem
, vol.45
, Issue.17
, pp. 3569-3572
-
-
Pellicciari, R.1
Fiorucci, S.2
Camaioni, E.3
-
137
-
-
78650769613
-
Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes
-
Vignozzi L., Morelli A., Filippi S., et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med: 2011; 8 1 57 77
-
(2011)
J Sex Med
, vol.8
, Issue.1
, pp. 57-77
-
-
Vignozzi, L.1
Morelli, A.2
Filippi, S.3
-
138
-
-
71449109826
-
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
-
Wang X. X., Jiang T., Shen Y., et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol: 2009; 297 6 F1587 F1596
-
(2009)
Am J Physiol Renal Physiol
, vol.297
, Issue.6
, pp. F1587-F1596
-
-
Wang, X.X.1
Jiang, T.2
Shen, Y.3
-
139
-
-
78049299629
-
Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model
-
Wang X. X., Jiang T., Shen Y., et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes: 2010; 59 11 2916 2927
-
(2010)
Diabetes
, vol.59
, Issue.11
, pp. 2916-2927
-
-
Wang, X.X.1
Jiang, T.2
Shen, Y.3
-
140
-
-
84929266699
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
-
NASH Clinical Research Network
-
Neuschwander-Tetri B. A., Loomba R., Sanyal A. J., et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet: 2015; 385 9972 956 965
-
(2015)
Lancet
, vol.385
, Issue.9972
, pp. 956-965
-
-
Neuschwander-Tetri, B.A.1
Loomba, R.2
Sanyal, A.J.3
-
141
-
-
77950613528
-
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
-
Cipriani S., Mencarelli A., Palladino G., Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res: 2010; 51 4 771 784
-
(2010)
J Lipid Res
, vol.51
, Issue.4
, pp. 771-784
-
-
Cipriani, S.1
Mencarelli, A.2
Palladino, G.3
Fiorucci, S.4
-
142
-
-
84925226080
-
The immunomodulatory role of bile acids
-
Sipka S., Bruckner G. The immunomodulatory role of bile acids. Int Arch Allergy Immunol: 2014; 165 1 1 8
-
(2014)
Int Arch Allergy Immunol
, vol.165
, Issue.1
, pp. 1-8
-
-
Sipka, S.1
Bruckner, G.2
-
143
-
-
56149126257
-
Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: New insights into hepatic inflammation
-
Wagner M., Zollner G., Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: New insights into hepatic inflammation. Hepatology: 2008; 48 5 1383 1386
-
(2008)
Hepatology
, vol.48
, Issue.5
, pp. 1383-1386
-
-
Wagner, M.1
Zollner, G.2
Trauner, M.3
-
144
-
-
77149159568
-
The bile acid receptor FXR is a modulator of intestinal innate immunity
-
Vavassori P., Mencarelli A., Renga B., Distrutti E., Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol: 2009; 183 10 6251 6261
-
(2009)
J Immunol
, vol.183
, Issue.10
, pp. 6251-6261
-
-
Vavassori, P.1
Mencarelli, A.2
Renga, B.3
Distrutti, E.4
Fiorucci, S.5
-
145
-
-
79952535597
-
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
-
Gadaleta R. M., van Erpecum K. J., Oldenburg B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut: 2011; 60 4 463 472
-
(2011)
Gut
, vol.60
, Issue.4
, pp. 463-472
-
-
Gadaleta, R.M.1
Van Erpecum, K.J.2
Oldenburg, B.3
-
146
-
-
61949324741
-
Antiatherosclerotic effect of farnesoid X receptor
-
Mencarelli A., Renga B., Distrutti E., Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol: 2009; 296 2 H272 H281
-
(2009)
Am J Physiol Heart Circ Physiol
, vol.296
, Issue.2
, pp. H272-H281
-
-
Mencarelli, A.1
Renga, B.2
Distrutti, E.3
Fiorucci, S.4
-
147
-
-
67650566600
-
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- And apoE-/- mice
-
Hartman H. B., Gardell S. J., Petucci C. J., Wang S., Krueger J. A., Evans M. J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- And apoE-/- mice. J Lipid Res: 2009; 50 6 1090 1100
-
(2009)
J Lipid Res
, vol.50
, Issue.6
, pp. 1090-1100
-
-
Hartman, H.B.1
Gardell, S.J.2
Petucci, C.J.3
Wang, S.4
Krueger, J.A.5
Evans, M.J.6
-
148
-
-
84869205703
-
Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice
-
Hambruch E., Miyazaki-Anzai S., Hahn U., et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther: 2012; 343 3 556 567
-
(2012)
J Pharmacol Exp Ther
, vol.343
, Issue.3
, pp. 556-567
-
-
Hambruch, E.1
Miyazaki-Anzai, S.2
Hahn, U.3
-
149
-
-
36349013143
-
Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration
-
Li Y. T., Swales K. E., Thomas G. J., Warner T. D., Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol: 2007; 27 12 2606 2611
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, Issue.12
, pp. 2606-2611
-
-
Li, Y.T.1
Swales, K.E.2
Thomas, G.J.3
Warner, T.D.4
Bishop-Bailey, D.5
-
150
-
-
0033172845
-
Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
-
Trauner M., Graziadei I. W. Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther: 1999; 13 8 979 996
-
(1999)
Aliment Pharmacol Ther
, vol.13
, Issue.8
, pp. 979-996
-
-
Trauner, M.1
Graziadei, I.W.2
-
151
-
-
84862144999
-
Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice
-
Tsuchida T., Shiraishi M., Ohta T., Sakai K., Ishii S. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism: 2012; 61 7 944 953
-
(2012)
Metabolism
, vol.61
, Issue.7
, pp. 944-953
-
-
Tsuchida, T.1
Shiraishi, M.2
Ohta, T.3
Sakai, K.4
Ishii, S.5
-
152
-
-
33748069813
-
Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes
-
Ozcan U., Yilmaz E., Ozcan L., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science: 2006; 313 5790 1137 1140
-
(2006)
Science
, vol.313
, Issue.5790
, pp. 1137-1140
-
-
Ozcan, U.1
Yilmaz, E.2
Ozcan, L.3
-
153
-
-
84904012910
-
Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice
-
Legry V., Van Rooyen D. M., Lambert B., et al. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice. Clin Sci (Lond): 2014; 127 7 507 518
-
(2014)
Clin Sci (Lond)
, vol.127
, Issue.7
, pp. 507-518
-
-
Legry, V.1
Van Rooyen, D.M.2
Lambert, B.3
-
154
-
-
83755181906
-
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury
-
Moustafa T., Fickert P., Magnes C., et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology: 2012; 142 1 140 151.e12
-
(2012)
Gastroenterology
, vol.142
, Issue.1
, pp. 140-151e12
-
-
Moustafa, T.1
Fickert, P.2
Magnes, C.3
-
155
-
-
77952561299
-
Bile acids as regulators of hepatic lipid and glucose metabolism
-
Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis: 2010; 28 1 220 224
-
(2010)
Dig Dis
, vol.28
, Issue.1
, pp. 220-224
-
-
Trauner, M.1
Claudel, T.2
Fickert, P.3
Moustafa, T.4
Wagner, M.5
-
156
-
-
79851511413
-
Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis
-
Beraza N., Ofner-Ziegenfuss L., Ehedego H., et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut: 2011; 60 3 387 396
-
(2011)
Gut
, vol.60
, Issue.3
, pp. 387-396
-
-
Beraza, N.1
Ofner-Ziegenfuss, L.2
Ehedego, H.3
-
157
-
-
84920401295
-
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
-
Jiang C., Xie C., Li F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest: 2015; 125 1 386 402
-
(2015)
J Clin Invest
, vol.125
, Issue.1
, pp. 386-402
-
-
Jiang, C.1
Xie, C.2
Li, F.3
-
158
-
-
84887960056
-
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
-
Li F., Jiang C., Krausz K. W., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun: 2013; 4 2384
-
(2013)
Nat Commun
, vol.4
, pp. 2384
-
-
Li, F.1
Jiang, C.2
Krausz, K.W.3
-
159
-
-
78049522194
-
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
-
Tilg H., Moschen A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology: 2010; 52 5 1836 1846
-
(2010)
Hepatology
, vol.52
, Issue.5
, pp. 1836-1846
-
-
Tilg, H.1
Moschen, A.R.2
-
160
-
-
84880664792
-
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
-
Mudaliar S., Henry R. R., Sanyal A. J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 3 574 82.e1
-
(2013)
Gastroenterology
, vol.145
, Issue.3
, pp. 574-82e1
-
-
Mudaliar, S.1
Henry, R.R.2
Sanyal, A.J.3
-
161
-
-
33645738747
-
Endocrine functions of bile acids
-
Houten S. M., Watanabe M., Auwerx J. Endocrine functions of bile acids. EMBO J: 2006; 25 7 1419 1425
-
(2006)
EMBO J
, vol.25
, Issue.7
, pp. 1419-1425
-
-
Houten, S.M.1
Watanabe, M.2
Auwerx, J.3
-
162
-
-
0036218724
-
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element
-
Claudel T., Sturm E., Duez H., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest: 2002; 109 7 961 971
-
(2002)
J Clin Invest
, vol.109
, Issue.7
, pp. 961-971
-
-
Claudel, T.1
Sturm, E.2
Duez, H.3
-
163
-
-
26244441014
-
The farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism
-
Claudel T., Staels B., Kuipers F. The farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol: 2005; 25 10 2020 2030
-
(2005)
Arterioscler Thromb Vasc Biol
, vol.25
, Issue.10
, pp. 2020-2030
-
-
Claudel, T.1
Staels, B.2
Kuipers, F.3
-
165
-
-
84863427742
-
Non-alcoholic fatty liver disease: The bile acid-activated farnesoid x receptor as an emerging treatment target
-
Fuchs M. Non-alcoholic fatty liver disease: The bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids: 2012; 2012 934396
-
(2012)
J Lipids
, vol.2012
, pp. 934396
-
-
Fuchs, M.1
-
166
-
-
77956189968
-
The inflamed liver and atherosclerosis: A link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk
-
Alkhouri N., Tamimi T. A., Yerian L., Lopez R., Zein N. N., Feldstein A. E. The inflamed liver and atherosclerosis: A link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci: 2010; 55 9 2644 2650
-
(2010)
Dig Dis Sci
, vol.55
, Issue.9
, pp. 2644-2650
-
-
Alkhouri, N.1
Tamimi, T.A.2
Yerian, L.3
Lopez, R.4
Zein, N.N.5
Feldstein, A.E.6
-
167
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio L. L., Drucker D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology: 2007; 132 6 2131 2157
-
(2007)
Gastroenterology
, vol.132
, Issue.6
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
168
-
-
84937053742
-
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
-
TECOS Study Group
-
Green J. B., Bethel M. A., Armstrong P. W., et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med: 2015; 373 3 232 242
-
(2015)
N Engl J Med
, vol.373
, Issue.3
, pp. 232-242
-
-
Green, J.B.1
Bethel, M.A.2
Armstrong, P.W.3
-
169
-
-
84976223148
-
Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
-
Carbone L. J., Angus P. W., Yeomans N. D. Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol: 2015
-
(2015)
J Gastroenterol Hepatol
-
-
Carbone, L.J.1
Angus, P.W.2
Yeomans, N.D.3
-
170
-
-
84958193043
-
-
ClinicalTrials.com. 2015. Available at: Accessed January 3, 2016
-
ClinicalTrials.com. 2015. Obeticholic acid. Available at: https://clinicaltrials.gov/ct2/results?term=fxr+fg. Accessed January 3, 2016
-
Obeticholic acid
-
-
-
171
-
-
77249102583
-
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance
-
Schreuder T. C., Marsman H. A., Lenicek M., et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol: 2010; 298 3 G440 G445
-
(2010)
Am J Physiol Gastrointest Liver Physiol
, vol.298
, Issue.3
, pp. G440-G445
-
-
Schreuder, T.C.1
Marsman, H.A.2
Lenicek, M.3
-
172
-
-
84879468929
-
Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease
-
Alisi A., Ceccarelli S., Panera N., et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS ONE: 2013; 8 6 e67160
-
(2013)
PLoS ONE
, vol.8
, Issue.6
, pp. e67160
-
-
Alisi, A.1
Ceccarelli, S.2
Panera, N.3
-
173
-
-
84885382835
-
A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass
-
Gerhard G. S., Styer A. M., Wood G. C., et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care: 2013; 36 7 1859 1864
-
(2013)
Diabetes Care
, vol.36
, Issue.7
, pp. 1859-1864
-
-
Gerhard, G.S.1
Styer, A.M.2
Wood, G.C.3
-
174
-
-
84876209742
-
Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids
-
Kohli R., Bradley D., Setchell K. D., Eagon J. C., Abumrad N., Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab: 2013; 98 4 E708 E712
-
(2013)
J Clin Endocrinol Metab
, vol.98
, Issue.4
, pp. E708-E712
-
-
Kohli, R.1
Bradley, D.2
Setchell, K.D.3
Eagon, J.C.4
Abumrad, N.5
Klein, S.6
-
175
-
-
84885298843
-
Mechanisms underlying weight loss after bariatric surgery
-
Miras A. D., le Roux C. W. Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol: 2013; 10 10 575 584
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, Issue.10
, pp. 575-584
-
-
Miras, A.D.1
Le Roux, C.W.2
-
176
-
-
84898051705
-
FXR is a molecular target for the effects of vertical sleeve gastrectomy
-
Ryan K. K., Tremaroli V., Clemmensen C., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature: 2014; 509 7499 183 188
-
(2014)
Nature
, vol.509
, Issue.7499
, pp. 183-188
-
-
Ryan, K.K.1
Tremaroli, V.2
Clemmensen, C.3
-
177
-
-
84898030895
-
FXR: The key to benefits in bariatric surgery?
-
Kuipers F., Groen A. K. FXR: The key to benefits in bariatric surgery? Nat Med: 2014; 20 4 337 338
-
(2014)
Nat Med
, vol.20
, Issue.4
, pp. 337-338
-
-
Kuipers, F.1
Groen, A.K.2
-
178
-
-
1542515099
-
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
-
Lindor K. D., Kowdley K. V., Heathcote E. J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology: 2004; 39 3 770 778
-
(2004)
Hepatology
, vol.39
, Issue.3
, pp. 770-778
-
-
Lindor, K.D.1
Kowdley, K.V.2
Heathcote, E.J.3
-
179
-
-
77955699301
-
High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial
-
NASH Study Group
-
Leuschner U. F., Lindenthal B., Herrmann G., et al. NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. Hepatology: 2010; 52 2 472 479
-
(2010)
Hepatology
, vol.52
, Issue.2
, pp. 472-479
-
-
Leuschner, U.F.1
Lindenthal, B.2
Herrmann, G.3
-
180
-
-
79954764140
-
A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis
-
FRESGUN
-
Ratziu V., de Ledinghen V., Oberti F., et al. FRESGUN. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol: 2011; 54 5 1011 1019
-
(2011)
J Hepatol
, vol.54
, Issue.5
, pp. 1011-1019
-
-
Ratziu, V.1
De Ledinghen, V.2
Oberti, F.3
-
181
-
-
84929607710
-
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
-
Mueller M., Thorell A., Claudel T., et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol: 2015; 62 6 1398 1404
-
(2015)
J Hepatol
, vol.62
, Issue.6
, pp. 1398-1404
-
-
Mueller, M.1
Thorell, A.2
Claudel, T.3
-
182
-
-
34248198871
-
Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice
-
Flowers J. B., Rabaglia M. E., Schueler K. L., et al. Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes: 2007; 56 5 1228 1239
-
(2007)
Diabetes
, vol.56
, Issue.5
, pp. 1228-1239
-
-
Flowers, J.B.1
Rabaglia, M.E.2
Schueler, K.L.3
-
183
-
-
33644821916
-
Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans
-
Hulver M. W., Berggren J. R., Carper M. J., et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab: 2005; 2 4 251 261
-
(2005)
Cell Metab
, vol.2
, Issue.4
, pp. 251-261
-
-
Hulver, M.W.1
Berggren, J.R.2
Carper, M.J.3
-
184
-
-
84918843434
-
The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease
-
FLORA Group
-
Safadi R., Konikoff F. M., Mahamid M., et al. FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol: 2014; 12 12 2085 91.e1
-
(2014)
Clin Gastroenterol Hepatol
, vol.12
, Issue.12
, pp. 2085-91e1
-
-
Safadi, R.1
Konikoff, F.M.2
Mahamid, M.3
-
185
-
-
2342652187
-
Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver
-
Dobrzyn P., Dobrzyn A., Miyazaki M., et al. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc Natl Acad Sci U S A: 2004; 101 17 6409 6414
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, Issue.17
, pp. 6409-6414
-
-
Dobrzyn, P.1
Dobrzyn, A.2
Miyazaki, M.3
-
186
-
-
0342316532
-
Oxysterols: Modulators of cholesterol metabolism and other processes
-
Schroepfer Jr. G. J. Oxysterols: Modulators of cholesterol metabolism and other processes. Physiol Rev: 2000; 80 1 361 554
-
(2000)
Physiol Rev
, vol.80
, Issue.1
, pp. 361-554
-
-
Schroepfer, G.J.1
-
187
-
-
0037192797
-
Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors
-
Joseph S. B., Laffitte B. A., Patel P. H., et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem: 2002; 277 13 11019 11025
-
(2002)
J Biol Chem
, vol.277
, Issue.13
, pp. 11019-11025
-
-
Joseph, S.B.1
Laffitte, B.A.2
Patel, P.H.3
-
188
-
-
0036251153
-
SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver
-
Horton J. D., Goldstein J. L., Brown M. S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest: 2002; 109 9 1125 1131
-
(2002)
J Clin Invest
, vol.109
, Issue.9
, pp. 1125-1131
-
-
Horton, J.D.1
Goldstein, J.L.2
Brown, M.S.3
-
189
-
-
64749108682
-
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia
-
Kratzer A., Buchebner M., Pfeifer T., et al. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res: 2009; 50 2 312 326
-
(2009)
J Lipid Res
, vol.50
, Issue.2
, pp. 312-326
-
-
Kratzer, A.1
Buchebner, M.2
Pfeifer, T.3
-
190
-
-
79954596966
-
Liver x receptors in atherosclerosis and inflammation
-
Im S. S., Osborne T. F. Liver x receptors in atherosclerosis and inflammation. Circ Res: 2011; 108 8 996 1001
-
(2011)
Circ Res
, vol.108
, Issue.8
, pp. 996-1001
-
-
Im, S.S.1
Osborne, T.F.2
-
191
-
-
77956365905
-
The liver X receptor: Control of cellular lipid homeostasis and beyond Implications for drug design
-
Oosterveer M. H., Grefhorst A., Groen A. K., Kuipers F. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. Prog Lipid Res: 2010; 49 4 343 352
-
(2010)
Prog Lipid Res
, vol.49
, Issue.4
, pp. 343-352
-
-
Oosterveer, M.H.1
Grefhorst, A.2
Groen, A.K.3
Kuipers, F.4
-
192
-
-
0037072732
-
Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles
-
Grefhorst A., Elzinga B. M., Voshol P. J., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem: 2002; 277 37 34182 34190
-
(2002)
J Biol Chem
, vol.277
, Issue.37
, pp. 34182-34190
-
-
Grefhorst, A.1
Elzinga, B.M.2
Voshol, P.J.3
-
193
-
-
33846864235
-
Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha
-
van der Veen J. N., Havinga R., Bloks V. W., Groen A. K., Kuipers F. Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha. J Lipid Res: 2007; 48 2 337 347
-
(2007)
J Lipid Res
, vol.48
, Issue.2
, pp. 337-347
-
-
Van Der Veen, J.N.1
Havinga, R.2
Bloks, V.W.3
Groen, A.K.4
Kuipers, F.5
-
194
-
-
0038353226
-
Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor
-
Inaba T., Matsuda M., Shimamura M., et al. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem: 2003; 278 24 21344 21351
-
(2003)
J Biol Chem
, vol.278
, Issue.24
, pp. 21344-21351
-
-
Inaba, T.1
Matsuda, M.2
Shimamura, M.3
-
195
-
-
0037072759
-
ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase
-
Shimizugawa T., Ono M., Shimamura M., et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem: 2002; 277 37 33742 33748
-
(2002)
J Biol Chem
, vol.277
, Issue.37
, pp. 33742-33748
-
-
Shimizugawa, T.1
Ono, M.2
Shimamura, M.3
-
196
-
-
38649096259
-
Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis
-
Zhou J., Febbraio M., Wada T., et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology: 2008; 134 2 556 567
-
(2008)
Gastroenterology
, vol.134
, Issue.2
, pp. 556-567
-
-
Zhou, J.1
Febbraio, M.2
Wada, T.3
-
197
-
-
40549125618
-
ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver
-
Denechaud P. D., Bossard P., Lobaccaro J. M., et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest: 2008; 118 3 956 964
-
(2008)
J Clin Invest
, vol.118
, Issue.3
, pp. 956-964
-
-
Denechaud, P.D.1
Bossard, P.2
Lobaccaro, J.M.3
-
198
-
-
84924281209
-
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
-
Griffett K., Welch R. D., Flaveny C. A., Kolar G. R., Neuschwander-Tetri B. A., Burris T. P. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol Metab: 2015; 4 4 353 357
-
(2015)
Mol Metab
, vol.4
, Issue.4
, pp. 353-357
-
-
Griffett, K.1
Welch, R.D.2
Flaveny, C.A.3
Kolar, G.R.4
Neuschwander-Tetri, B.A.5
Burris, T.P.6
-
199
-
-
84912525212
-
Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease
-
Ahn S. B., Jang K., Jun D. W., Lee B. H., Shin K. J. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci: 2014; 59 12 2975 2982
-
(2014)
Dig Dis Sci
, vol.59
, Issue.12
, pp. 2975-2982
-
-
Ahn, S.B.1
Jang, K.2
Jun, D.W.3
Lee, B.H.4
Shin, K.J.5
-
200
-
-
67049144914
-
Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants
-
Katz A., Udata C., Ott E., et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol: 2009; 49 6 643 649
-
(2009)
J Clin Pharmacol
, vol.49
, Issue.6
, pp. 643-649
-
-
Katz, A.1
Udata, C.2
Ott, E.3
-
201
-
-
84884300669
-
The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease
-
Ducheix S., Montagner A., Theodorou V., Ferrier L., Guillou H. The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. Biochem Pharmacol: 2013; 86 1 96 105
-
(2013)
Biochem Pharmacol
, vol.86
, Issue.1
, pp. 96-105
-
-
Ducheix, S.1
Montagner, A.2
Theodorou, V.3
Ferrier, L.4
Guillou, H.5
-
202
-
-
84897071025
-
Vitamin D metabolism, mechanism of action, and clinical applications
-
Bikle D. D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol: 2014; 21 3 319 329
-
(2014)
Chem Biol
, vol.21
, Issue.3
, pp. 319-329
-
-
Bikle, D.D.1
-
203
-
-
84883259255
-
Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?
-
Kwok R. M., Torres D. M., Harrison S. A. Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association? Hepatology: 2013; 58 3 1166 1174
-
(2013)
Hepatology
, vol.58
, Issue.3
, pp. 1166-1174
-
-
Kwok, R.M.1
Torres, D.M.2
Harrison, S.A.3
-
204
-
-
79955042823
-
Vitamin D and the Vitamin D receptor in liver pathophysiology
-
Zúñiga S., Firrincieli D., Housset C., Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol: 2011; 35 4 295 302
-
(2011)
Clin Res Hepatol Gastroenterol
, vol.35
, Issue.4
, pp. 295-302
-
-
Zúñiga, S.1
Firrincieli, D.2
Housset, C.3
Chignard, N.4
-
205
-
-
84867746418
-
Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism
-
Yin Y., Yu Z., Xia M., Luo X., Lu X., Ling W. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest: 2012; 42 11 1189 1196
-
(2012)
Eur J Clin Invest
, vol.42
, Issue.11
, pp. 1189-1196
-
-
Yin, Y.1
Yu, Z.2
Xia, M.3
Luo, X.4
Lu, X.5
Ling, W.6
-
206
-
-
84876279910
-
The role of Vitamin D receptor in innate and adaptive immunity: A study in hereditary Vitamin D-resistant rickets patients
-
Tiosano D., Wildbaum G., Gepstein V., et al. The role of vitamin D receptor in innate and adaptive immunity: A study in hereditary vitamin D-resistant rickets patients. J Clin Endocrinol Metab: 2013; 98 4 1685 1693
-
(2013)
J Clin Endocrinol Metab
, vol.98
, Issue.4
, pp. 1685-1693
-
-
Tiosano, D.1
Wildbaum, G.2
Gepstein, V.3
-
207
-
-
78649816415
-
Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression
-
Chang S. H., Chung Y., Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem: 2010; 285 50 38751 38755
-
(2010)
J Biol Chem
, vol.285
, Issue.50
, pp. 38751-38755
-
-
Chang, S.H.1
Chung, Y.2
Dong, C.3
-
208
-
-
10044281540
-
Mounting evidence for Vitamin D as an environmental factor affecting autoimmune disease prevalence
-
Cantorna M. T., Mahon B. D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood): 2004; 229 11 1136 1142
-
(2004)
Exp Biol Med (Maywood)
, vol.229
, Issue.11
, pp. 1136-1142
-
-
Cantorna, M.T.1
Mahon, B.D.2
-
209
-
-
84876928036
-
A Vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
-
Ding N., Yu R. T., Subramaniam N., et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell: 2013; 153 3 601 613
-
(2013)
Cell
, vol.153
, Issue.3
, pp. 601-613
-
-
Ding, N.1
Yu, R.T.2
Subramaniam, N.3
-
210
-
-
84922707696
-
Vitamin D: A new player in non-alcoholic fatty liver disease?
-
Eliades M., Spyrou E. Vitamin D: A new player in non-alcoholic fatty liver disease? World J Gastroenterol: 2015; 21 6 1718 1727
-
(2015)
World J Gastroenterol
, vol.21
, Issue.6
, pp. 1718-1727
-
-
Eliades, M.1
Spyrou, E.2
-
211
-
-
0037364216
-
Impaired insulin secretory capacity in mice lacking a functional Vitamin D receptor
-
Zeitz U., Weber K., Soegiarto D. W., Wolf E., Balling R., Erben R. G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J: 2003; 17 3 509 511
-
(2003)
FASEB J
, vol.17
, Issue.3
, pp. 509-511
-
-
Zeitz, U.1
Weber, K.2
Soegiarto, D.W.3
Wolf, E.4
Balling, R.5
Erben, R.G.6
-
212
-
-
84881476917
-
No significant association between Vitamin D and nonalcoholic fatty liver disease in a Chinese population
-
Li L., Zhang L., Pan S., Wu X., Yin X. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population. Dig Dis Sci: 2013; 58 8 2376 2382
-
(2013)
Dig Dis Sci
, vol.58
, Issue.8
, pp. 2376-2382
-
-
Li, L.1
Zhang, L.2
Pan, S.3
Wu, X.4
Yin, X.5
-
213
-
-
84875506039
-
High serum Vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome
-
Rhee E-J, Kim M. K., Park S. E., et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J: 2013; 60 6 743 752
-
(2013)
Endocr J
, vol.60
, Issue.6
, pp. 743-752
-
-
Rhee, E.-J.1
Kim, M.K.2
Park, S.E.3
-
214
-
-
84879735651
-
Meta-analysis: Vitamin D and non-alcoholic fatty liver disease
-
Eliades M., Spyrou E., Agrawal N., et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther: 2013; 38 3 246 254
-
(2013)
Aliment Pharmacol Ther
, vol.38
, Issue.3
, pp. 246-254
-
-
Eliades, M.1
Spyrou, E.2
Agrawal, N.3
-
215
-
-
84902545822
-
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease
-
Dasarathy J., Periyalwar P., Allampati S., et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int: 2014; 34 6 e118 e127
-
(2014)
Liver Int
, vol.34
, Issue.6
, pp. e118-e127
-
-
Dasarathy, J.1
Periyalwar, P.2
Allampati, S.3
-
216
-
-
84896945009
-
Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease
-
Nobili V., Giorgio V., Liccardo D., et al. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol: 2014; 170 4 547 553
-
(2014)
Eur J Endocrinol
, vol.170
, Issue.4
, pp. 547-553
-
-
Nobili, V.1
Giorgio, V.2
Liccardo, D.3
-
217
-
-
84655169612
-
The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: The NHS and the HPFS
-
Vaidya A., Williams J. S., Forman J. P. The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: The NHS and the HPFS. Obesity (Silver Spring): 2012; 20 1 186 191
-
(2012)
Obesity (Silver Spring)
, vol.20
, Issue.1
, pp. 186-191
-
-
Vaidya, A.1
Williams, J.S.2
Forman, J.P.3
-
218
-
-
84890142663
-
Vitamin D status and ill health: A systematic review
-
Autier P., Boniol M., Pizot C., Mullie P. Vitamin D status and ill health: A systematic review. Lancet Diabetes Endocrinol: 2014; 2 1 76 89
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, Issue.1
, pp. 76-89
-
-
Autier, P.1
Boniol, M.2
Pizot, C.3
Mullie, P.4
-
219
-
-
84920055682
-
Vitamin D deficiency in chronic liver disease
-
Iruzubieta P., Terán Á, Crespo J., Fábrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol: 2014; 6 12 901 915
-
(2014)
World J Hepatol
, vol.6
, Issue.12
, pp. 901-915
-
-
Iruzubieta, P.1
Terán, Á.2
Crespo, J.3
Fábrega, E.4
-
220
-
-
84875244725
-
Nuclear receptors in nonalcoholic fatty liver disease
-
López-Velázquez J. A., Carrillo-Córdova L. D., Chávez-Tapia N. C., Uribe M., Méndez-Sánchez N. Nuclear receptors in nonalcoholic fatty liver disease. J Lipids: 2012; 2012 139875
-
(2012)
J Lipids
, vol.2012
, pp. 139875
-
-
López-Velázquez, J.A.1
Carrillo-Córdova, L.D.2
Chávez-Tapia, N.C.3
Uribe, M.4
Méndez-Sánchez, N.5
-
221
-
-
0023937933
-
Phenobarbital induction of cytochrome P-450 b,e genes is dependent on protein synthesis
-
Chianale J., Mulholland L., Traber P. G., Gumucio J. J. Phenobarbital induction of cytochrome P-450 b,e genes is dependent on protein synthesis. Hepatology: 1988; 8 2 327 331
-
(1988)
Hepatology
, vol.8
, Issue.2
, pp. 327-331
-
-
Chianale, J.1
Mulholland, L.2
Traber, P.G.3
Gumucio, J.J.4
-
222
-
-
0035185021
-
The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression
-
Nakae J., Kitamura T., Silver D. L., Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest: 2001; 108 9 1359 1367
-
(2001)
J Clin Invest
, vol.108
, Issue.9
, pp. 1359-1367
-
-
Nakae, J.1
Kitamura, T.2
Silver, D.L.3
Accili, D.4
-
223
-
-
39749171761
-
Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response
-
Moreau A., Vilarem M. J., Maurel P., Pascussi J. M. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm: 2008; 5 1 35 41
-
(2008)
Mol Pharm
, vol.5
, Issue.1
, pp. 35-41
-
-
Moreau, A.1
Vilarem, M.J.2
Maurel, P.3
Pascussi, J.M.4
-
225
-
-
33744948052
-
A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway
-
Zhou J., Zhai Y., Mu Y., et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem: 2006; 281 21 15013 15020
-
(2006)
J Biol Chem
, vol.281
, Issue.21
, pp. 15013-15020
-
-
Zhou, J.1
Zhai, Y.2
Mu, Y.3
-
226
-
-
84877798556
-
PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice
-
He J., Gao J., Xu M., et al. PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes: 2013; 62 6 1876 1887
-
(2013)
Diabetes
, vol.62
, Issue.6
, pp. 1876-1887
-
-
He, J.1
Gao, J.2
Xu, M.3
-
227
-
-
41149102969
-
Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression
-
Roth A., Looser R., Kaufmann M., et al. Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol Pharmacol: 2008; 73 4 1282 1289
-
(2008)
Mol Pharmacol
, vol.73
, Issue.4
, pp. 1282-1289
-
-
Roth, A.1
Looser, R.2
Kaufmann, M.3
-
228
-
-
73949117713
-
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease
-
Sookoian S., Castaño G. O., Burgueño A. L., Gianotti T. F., Rosselli M. S., Pirola C. J. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics: 2010; 20 1 1 8
-
(2010)
Pharmacogenet Genomics
, vol.20
, Issue.1
, pp. 1-8
-
-
Sookoian, S.1
Castaño, G.O.2
Burgueño, A.L.3
Gianotti, T.F.4
Rosselli, M.S.5
Pirola, C.J.6
-
229
-
-
85047693782
-
Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia
-
Pascussi J. M., Robert A., Nguyen M., et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest: 2005; 115 1 177 186
-
(2005)
J Clin Invest
, vol.115
, Issue.1
, pp. 177-186
-
-
Pascussi, J.M.1
Robert, A.2
Nguyen, M.3
-
230
-
-
0021850197
-
Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects
-
Lahtela J. T., Arranto A. J., Sotaniemi E. A. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes: 1985; 34 9 911 916
-
(1985)
Diabetes
, vol.34
, Issue.9
, pp. 911-916
-
-
Lahtela, J.T.1
Arranto, A.J.2
Sotaniemi, E.A.3
-
231
-
-
84929155646
-
Targeting xenobiotic receptors PXR and CAR in human diseases
-
Banerjee M., Robbins D., Chen T. Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov Today: 2015; 20 5 618 628
-
(2015)
Drug Discov Today
, vol.20
, Issue.5
, pp. 618-628
-
-
Banerjee, M.1
Robbins, D.2
Chen, T.3
-
232
-
-
84866738222
-
Targeting xenobiotic receptors PXR and CAR for metabolic diseases
-
Gao J., Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci: 2012; 33 10 552 558
-
(2012)
Trends Pharmacol Sci
, vol.33
, Issue.10
, pp. 552-558
-
-
Gao, J.1
Xie, W.2
-
233
-
-
84878258395
-
Pregnane X receptor agonists impair postprandial glucose tolerance
-
Rysä J., Buler M., Savolainen M. J., Ruskoaho H., Hakkola J., Hukkanen J. Pregnane X receptor agonists impair postprandial glucose tolerance. Clin Pharmacol Ther: 2013; 93 6 556 563
-
(2013)
Clin Pharmacol Ther
, vol.93
, Issue.6
, pp. 556-563
-
-
Rysä, J.1
Buler, M.2
Savolainen, M.J.3
Ruskoaho, H.4
Hakkola, J.5
Hukkanen, J.6
-
235
-
-
84895801586
-
REV-ERB and ROR nuclear receptors as drug targets
-
Kojetin D. J., Burris T. P. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov: 2014; 13 3 197 216
-
(2014)
Nat Rev Drug Discov
, vol.13
, Issue.3
, pp. 197-216
-
-
Kojetin, D.J.1
Burris, T.P.2
-
236
-
-
84907904466
-
Targeting Th17 cells in autoimmune diseases
-
Yang J., Sundrud M. S., Skepner J., Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci: 2014; 35 10 493 500
-
(2014)
Trends Pharmacol Sci
, vol.35
, Issue.10
, pp. 493-500
-
-
Yang, J.1
Sundrud, M.S.2
Skepner, J.3
Yamagata, T.4
-
237
-
-
84885112550
-
Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis
-
Vonghia L., Michielsen P., Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci: 2013; 14 10 19867 19890
-
(2013)
Int J Mol Sci
, vol.14
, Issue.10
, pp. 19867-19890
-
-
Vonghia, L.1
Michielsen, P.2
Francque, S.3
-
238
-
-
80053651902
-
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
-
Tang Y., Bian Z., Zhao L., et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol: 2011; 166 2 281 290
-
(2011)
Clin Exp Immunol
, vol.166
, Issue.2
, pp. 281-290
-
-
Tang, Y.1
Bian, Z.2
Zhao, L.3
-
239
-
-
84865461464
-
Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice
-
3
-
Meng F., Wang K., Aoyama T., et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology: 2012; 143 3 765 76.e1, 3
-
(2012)
Gastroenterology
, vol.143
, Issue.3
, pp. 765-76e1
-
-
Meng, F.1
Wang, K.2
Aoyama, T.3
-
240
-
-
84946722042
-
IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression
-
Giles D. A., Moreno-Fernandez M. E., Divanovic S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets: 2015; 16 12 1315 1323
-
(2015)
Curr Drug Targets
, vol.16
, Issue.12
, pp. 1315-1323
-
-
Giles, D.A.1
Moreno-Fernandez, M.E.2
Divanovic, S.3
-
241
-
-
58149512325
-
Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women
-
Sumarac-Dumanovic M., Stevanovic D., Ljubic A., et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes: 2009; 33 1 151 156
-
(2009)
Int J Obes
, vol.33
, Issue.1
, pp. 151-156
-
-
Sumarac-Dumanovic, M.1
Stevanovic, D.2
Ljubic, A.3
-
242
-
-
84885112550
-
Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis
-
Vonghia L., Michielsen P., Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci: 2013; 14 10 19867 19890
-
(2013)
Int J Mol Sci
, vol.14
, Issue.10
, pp. 19867-19890
-
-
Vonghia, L.1
Michielsen, P.2
Francque, S.3
-
243
-
-
84865772592
-
Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications
-
Huh J. R., Littman D. R. Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications. Eur J Immunol: 2012; 42 9 2232 2237
-
(2012)
Eur J Immunol
, vol.42
, Issue.9
, pp. 2232-2237
-
-
Huh, J.R.1
Littman, D.R.2
-
244
-
-
77955362775
-
Chronic inflammation in obesity and the metabolic syndrome
-
Monteiro R., Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm: 2010; 2010
-
(2010)
Mediators Inflamm
, vol.2010
-
-
Monteiro, R.1
Azevedo, I.2
-
245
-
-
84906730677
-
Is serum Interleukin-17 associated with early atherosclerosis in obese patients?
-
Tarantino G., Costantini S., Finelli C., et al. Is serum Interleukin-17 associated with early atherosclerosis in obese patients? J Transl Med: 2014; 12 214
-
(2014)
J Transl Med
, vol.12
, pp. 214
-
-
Tarantino, G.1
Costantini, S.2
Finelli, C.3
-
246
-
-
77649138576
-
Circadian rhythms and metabolic syndrome: From experimental genetics to human disease
-
Maury E., Ramsey K. M., Bass J. Circadian rhythms and metabolic syndrome: From experimental genetics to human disease. Circ Res: 2010; 106 3 447 462
-
(2010)
Circ Res
, vol.106
, Issue.3
, pp. 447-462
-
-
Maury, E.1
Ramsey, K.M.2
Bass, J.3
-
247
-
-
84930379363
-
Clocking in: Chronobiology in rheumatoid arthritis
-
Buttgereit F., Smolen J. S., Coogan A. N., Cajochen C. Clocking in: chronobiology in rheumatoid arthritis. Nat Rev Rheumatol: 2015; 11 6 349 356
-
(2015)
Nat Rev Rheumatol
, vol.11
, Issue.6
, pp. 349-356
-
-
Buttgereit, F.1
Smolen, J.S.2
Coogan, A.N.3
Cajochen, C.4
-
248
-
-
77955980762
-
Chronotherapy and the molecular clock: Clinical implications in oncology
-
Innominato P. F., Lévi F. A., Bjarnason G. A. Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev: 2010; 62 9-10 979 1001
-
(2010)
Adv Drug Deliv Rev
, vol.62
, Issue.9-10
, pp. 979-1001
-
-
Innominato, P.F.1
Lévi, F.A.2
Bjarnason, G.A.3
|